Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL
Enrollment

269

Participants

Timeline

Start Date

October 28, 2015

Primary Completion Date

April 18, 2017

Study Completion Date

January 5, 2018

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Empagliflozin

DRUG

Placebo

DRUG

Placebo

For blinding purposes

Trial Locations (48)

456-0058

Nakayama Clinic, Aichi

277-0825

Kashiwa City Hospital, Chiba, Kashiwa

819-0168

Kunisaki Makoto Clinic, Fukuoka

810-0001

Saiseikai Fukuoka General Hospital, Fukuoka, Fukuoka

832-0059

Seiwakai Medical Corporation Nagata Hospital, Fukuoka, Yanagawa

371-0821

Saiseikai Maebashi Hospital, Gunma, Maebashi

721-0927

Nippon Kokan Fukuyama Hospital, Hiroshima, Fukuyama

080-0016

Jiyugaoka Yokoyama Naika Clinic, Hokkaido, Obihiro

080-0848

Jiyugaoka Yamada Clinic, Hokkaido, Obihiro

060-0011

Souen Diabetes Clinic, Hokkaido, Sapporo

657-0028

Kotani Diabetes Clinic, Hyogo, Kobe

663-8014

Nishinomiya Municipal Central Hospital, Hyogo, Nishinomiya

300-1207

Noritake Clinic, Ibaraki, Ushiku

761-8075

Yokoi Medical Clinic, Kagawa, I.M., Kagawa

891-0401

Fukumoto clinic, Kagoshima

892-0824

Izuro Imamura Hospital, Kagoshima, Kagoshima

895-0052

Wakamatsu Memorial Hospital, Kagoshima, Satsumasendai

243-0035

STOP DM SUZUKI DIABETES CLINIC, Kanagawa, I.M., Kanagawa, Atsugi

247-0056

Takai Naika Clinic, Kanagawa, Kamakura

210-0852

Kokan Clinic, Kanagawa, Kawasaki

604-8151

Yoshimasa Diabetes & Endocrine Clinic, Kyoto, Kyoto

615-0035

Medical Corporation KEISEIKAI Kajiyama clinic, Kyoto, Kyoto

985-0835

Saka General Clinic, Miyagi, Tagajo

399-8695

North Alps Medical Center Azumi Hospital, Nagano, Kitaazumi-gun

384-8588

Asama Nanroku Komoro Medical center, Nagano, Komoro

870-0039

Abe Clinic, Oita, Oita

708-0841

Tsuyama Chuo Hospital, Okayama, Tsuyama

530-0001

AMC Nishi-umeda Clinic, Osaka

582-0005

Shiraiwa Medical Clinic, Osaka

572-8567

Medical Corporation Kyojinkai Clinic Komatsu, Osaka, Neyagawa

559-0012

Minamiosaka Hospital, Osaka, Osaka

565-0853

OCROM Clinic, Osaka, Suita

362-8588

Ageo Central General Hospital, Saitama, Ageo

354-0031

Medical Corporation Kaishinkai Masunaga Clinic, Saitama, Fujimi

336-0963

Medical Corporation Fusa Shimizu Clinic Fusa, Saitama, Saitama

123-0845

Seiwa Clinic, Tokyo, Adachi-ku

113-8431

Juntendo University Hospital, Tokyo, Bunkyo-ku

101-0024

Chiyoda Houjin Clinic, Tokyo, Chiyoda-ku

102-0082

HDC Atlas Clinic, Tokyo, Chiyoda-ku

103-0027

Fukuwa Clinic, Tokyo, Chuo-ku

Tokyo-Eki Center-building Clinic, Tokyo, Chuo-ku

103-0028

Tokyo Center Clinic, Tokyo, Chuo-ku

144-0051

Shin Clinic, Tokyo, Ota-ku

169-0073

Shinjuku Research Park Clinic, Tokyo, Shinjuku-ku

131-0046

Sumida Chuou Hospital, Tokyo, Sumida-ku

991-8508

Sagae City Hospital, Yamagata, Sagae

990-0885

Clinic Sugiyama, Yamagata, Yamagata

400-8506

Yamanashi Prefectural Central Hospital, Yamanashi, Kofu

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY

NCT02589639 - Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter